Article

Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.

Breast International Group, and Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Brussels, Belgium.
The Lancet Oncology (Impact Factor: 24.73). 06/2011; 12(12):1162-8. DOI: 10.1016/S1470-2045(11)70117-6
Source: PubMed

ABSTRACT In this Personal View, we outline proposals for uniform collection of biospecimens obtained in neoadjuvant breast cancer trials undertaken by the Breast International Group (BIG) and the National Cancer Institute-sponsored North American Breast Cancer Group (NABCG). These proposals aim to standardise collection of high-quality specimens, with respect to both type and timing, to enhance and allow integration of results obtained from neoadjuvant trials done by several groups. They should be considered in parallel with recommendations for tissue-specimen collection and handling previously developed by BIG and NABCG. We propose that tumour tissue (formalin-fixed, paraffin-embedded and samples dedicated for molecular studies) should be taken at baseline, 1-3 weeks after the start of treatment, and at definitive surgery, with clear prioritisation in the study protocol of number, order, and preservation of samples to be gathered. This step should be accompanied by blood collection (plasma, serum, and whole blood) whenever possible. We advocate strongly a move towards one diagnostic and research biopsy procedure in all women with breast cancers potentially suitable for neoadjuvant treatment. If possible, patients should be referred at the outset to specialised centres to give them the opportunity to participate in neoadjuvant clinical trials, thereby avoiding several biopsy procedures.

0 Followers
 · 
180 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tailoring treatment strategies to individual patients requires the availability of reliable biomarkers. Despite important investment in biomarker research, few examples of successful biomarker-drug co-development are currently seen in clinical practice. The validity of a biomarker measurement may be affected by different pre-analytical, analytical and post-analytical factors. The lack of control or oversight of any of these factors may ultimately lead to failure in translating a promising research finding into clinical practice. In the present review, we put into perspective some of the obstacles to "precision" oncology, focusing on the technical and biological hurdles that may affect the validity of a biomarker result and, ultimately, the likelihood of a new targeted agent to reach the clinic.
    Cellular Oncology 09/2014; 38(1). DOI:10.1007/s13402-014-0192-6 · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Reliable stability and yield of RNA from breast cancer tissues are important for biobanking, clinical trials, and diagnostic testing. Aliquots of fresh primary tumor tissue from 17 surgically resected invasive breast cancers were placed into RNAlater at room temperature after tumor removal (baseline) and up to 3 hours thereafter or were snap frozen at baseline and 40 minutes thereafter. Samples were stored at -80°C until gene expression profiling with Affymetrix Human Gene U133A microarrays. We evaluated the effects of cold ischemic time (the time from tumor specimen removal to sample preservation) and sample preservation method on RNA yield, Bioanalyzer-based RNA integrity number, microarray-based 3'/5' expression ratios for assessing transcript integrity, and microarray-based measurement of single-gene and multigene expression signatures. The statistical significance of the effects was assessed using linear mixed effects regression models. All statistical tests were two-sided. Sample preservation in RNAlater statistically significantly improved RNA integrity compared with snap freezing as assessed by the RNA integrity number, which increased from 7.31 to 8.13 units (difference = 0.82 units, 95% confidence interval [CI] = 0.53 to 1.11 units, P < .001), and RNA yield, which increased threefold from 8.9 to 28.6 μg (difference = 19.7 μg, 95% CI = 14.1 to 25.3 μg, P < .001). Prolonged cold ischemic delay at room temperature before sample stabilization decreased the RNA integrity number by 0.12 units/h (95% CI = 0.02 to 0.23 units/h) compared with a projected average RNA integrity number of 7.39 if no delays were present (P = .008) and decreased the RNA yield by 1.5 μg/h (95% CI = 0 to 4 μg/h) from a baseline mean RNA yield of 33.5 μg if no delays were present (P = .019). Prolonged cold ischemia statistically significantly increased the 3'/5' ratio of control gene transcripts, particularly of STAT1 (P < .001). Snap freezing statistically significantly increased the 3'/5' ratio of three control transcripts (ACTB, GAPDH, and 18S rRNA). Expression levels of single genes and multigene signatures for breast cancer were largely unaffected by sample preservation method or cold ischemia. Sample preservation in RNAlater improves RNA yield and quality, whereas cold ischemia increases RNA fragmentation as measured by the 3'/5' expression ratio of control genes. However, expression levels of single genes and multigene signatures that are of diagnostic relevance in breast cancer were mostly unaffected by sample preservation method or prolonged cold ischemic duration.
    CancerSpectrum Knowledge Environment 12/2011; 103(24):1871-83. DOI:10.1093/jnci/djr438 · 15.16 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is the most frequent cancer in women in developed countries. Endocrine treatment is indicated to the majority of breast cancer patients. However, in some cases it does not work despite the current clinical indications. Eventually the resistance may develop in many of those who initially respond. Re-analysis of available breast cancer transcriptomic datasets using new multi-gene signatures associated with endocrine resistance may help to understand and overcome endocrine resistance. The goal of this project was to develop a bioinformatics pipeline to (i) select endocrine resistant cases from the available breast cancer datasets and (ii) classify the selected cases by multiple multi-gene signatures. The pipeline has been successfully designed and applied for classification of endocrine-resistant samples from 9 breast cancer datasets using 7 transcriptional signatures. The obtained results have been presented in a dedicated web site. The pipeline consists of: • Procedures for a manually curated selection of relevant datasets and signatures; • Procedures for semi-automatic data pre-processing, allowing cross-platform analysis; • A new, fully automated, classification algorithm (Iterative Consensus PAM). The main features of the developed classification algorithm include: • It is based on un-supervised partitioning; • It allows for “non-classifiable” samples; • The procedure does not require a training set; • The procedure can be used in a cross-platform context (Affymetrix & Illumina). The developed pipeline and web site may constitute a prototype for a future web-hub collecting (i) data on endocrine-resistant breast cancer specimens, (ii) collecting multi-gene signatures relevant to endocrine resistance and (iii) providing tools to apply the signatures to the data. The web-repository could provide a tool to integrate the data and signatures and to produce new clinical and biological knowledge about endocrine resistance in breast cancer.
    01/2012, Degree: MSc, Applied Bioinformatics, Cranfield University, UK, Supervisor: David Cameron and Sarah Morgan

Full-text

Download
45 Downloads
Available from
May 20, 2014